Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000705232 | SCV000834221 | pathogenic | Anophthalmia-microphthalmia syndrome | 2023-02-14 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the OTX2 gene (p.Leu212Valfs*82). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 78 amino acid(s) of the OTX2 protein and extend the protein by 4 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with OTX2-related conditions. This variant disrupts a region of the OTX2 protein in which other variant(s) (p.Ala236Ser) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |